Search
Displaying 271–280 of 664 for “retinitis clinical trial”
-
FFB Convenes Experts to Discuss Therapeutic Opportunities for Stargardt Disease
Research NewsMuch of the information and data shared during the meeting came out of ProgSTAR, the FFB-CRI-funded natural history study of 365 Stargardt disease patients.
-
Changing Someone’s Life: A New Video Emphasizes the Need to Support FFB’s Mission
Beacon StoriesAllison Corona is one of 40 people with Leber congenital amaurosis who’ve benefitted from a gene therapy clinical trial.
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
ARVO 2014: LCA Gene Therapy Recipient Featured During Keynote
Research News15-year-old Yannick Duwe transfixed the audience, describing how the treatment enabled him to use a computer instead of Braille, and work much easier and faster at school.
-
ARVO 2016: ProgSTAR, FFB-CRI's Stargardt Disease Patient Study, Highlighted
Research NewsWhen the study and the reports are completed, the ProgSTAR database will be made available to researchers and companies developing therapies.
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
-
A regularly-updated table of inherited retinal diseases and dry AMD clinical trials
-
Resource
Dr. Jacque Duncan, UCSF Professor of Clinical Ophthalmology, is currently working on therapies restoring vision for retinal degenerative diseases. Dr. Duncan has hope and optimism for the future that vision will be restored for those with retinal diseases, thanks in part by the Foundation’s work.
-
Apellis to Seek FDA Approval of its Dry AMD Drug
Research NewsKnown as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Research NewsUnlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
